Low-dose growth hormone is cardioprotective in uremia

Journal of the American Society of Nephrology

Volumn 19, Issue 9, 2008, Pages 1774-1783

  Rabkin, Ralph ^a,c   Awwad, Ibrahim ^b   Chen, Yu ^a   Ashley, Euan A ^a   Sun, Difei ^a   Sood, Sumita ^a   Clusin, William ^a   Heidenreich, Paul ^a   Piecha, Grzegorz ^b   Gross, Marie Luise ^b  

^a STANFORD UNIVERSITY   (United States)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; GROWTH HORMONE; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL WALL THICKENING; ARTICLE; CAPILLARY DENSITY; CAROTID ARTERY; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DRUG MEGADOSE; FIBROBLAST; HEART PROTECTION; LOW DRUG DOSE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; UREMIA; ANIMAL; ARTERY; BLOOD; BLOOD PRESSURE; BODY WEIGHT; DRUG EFFECT; GENE EXPRESSION; HEART MUSCLE; HEART VENTRICLE REMODELING; HEMATOCRIT; HEMODYNAMICS; HYPERTROPHIC CARDIOMYOPATHY; IMMUNOHISTOCHEMISTRY; METABOLISM; ORGAN SIZE; PATHOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; ARTERIES; BLOOD PRESSURE; BODY WEIGHT; CARDIOMYOPATHY, HYPERTROPHIC; GENE EXPRESSION; GROWTH HORMONE; HEMATOCRIT; HEMODYNAMICS; IMMUNOHISTOCHEMISTRY; MALE; MYOCARDIUM; ORGAN SIZE; RATS; RATS, SPRAGUE-DAWLEY; UREMIA; VENTRICULAR REMODELING;

EID: 54749089717     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2007121386     Document Type: Article

References (60)

1. London GM: Cardiovascular disease in chronic renal failure: Pathophysiologic aspects. Semin Dial 16: 85-94, 2003
2. Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, McAlister F, Garg AX: Chronic kidney disease and mortality risk: A systematic review. J Am Soc Nephrol 17: 2034-2047, 2006
3. Zoccali C: Traditional and emerging cardiovascular and renal risk factors: An epidemiologic perspective. Kidney Int 70: 26-33, 2006
4. Flynn JT: Cardiovascular disease in children with chronic renal failure. Growth Horm IGF Res 16[Suppl A]: S84-S90, 2006
5. Amann K, Ritz C, Adamczak M, Ritz E: Why is coronary heart disease of uraemic patients so frequent and so devastating? Nephrol Dial Transplant 18: 631-640, 2003
6. Herzog CA, Ma JZ, Collins AJ: Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 339: 799-805, 1998
7. Mall G, Huther W, Schneider J, Lundin P, Ritz E: Diffuse intermyocardiocytic fibrosis in uraemic patients. Nephrol Dial Transplant 5: 39-44, 1990
8. Tyralla K, Amann K: Morphology of the heart and arteries in renal failure. Kidney Int Suppl S80-S83, 2003
9. Amann K, Breitbach M, Ritz E, Mall G: Myocyte/capillary mismatch in the heart of uremic patients. J Am Soc Nephrol 9: 1018-1022, 1998
10. Amann K, Tornig J, Kugel B, Gross ML, Tyralla K, El-Shakmak A, Szabo A, Ritz E: Hyperphosphatemia aggravates cardiac fibrosis and microvascular disease in experimental uremia. Kidney Int 63: 1296-1301, 2003
11. Dikow R, Kihm LP, Zeier M, Kapitza J, Tornig J, Amann K, Tiefenbacher C, Ritz E: Increased infarct size in uremic rats: Reduced ischemia tolerance? J Am Soc Nephrol 15: 1530-1536, 2004
12. Periyasamy SM, Chen J, Cooney D, Carter P, Omran E, Tian J, Priyadarshi S, Bagrov A, Fedorova O, Malhotra D, Xie Z, Shapiro JI: Effects of uremic serum on isolated cardiac myocyte calcium cycling and contractile function. Kidney Int 60: 2367-2376, 2001
13. Climent V, Maran F, Pica A: Pharmacologic therapy in growth hormone disorders and the heart. Curr Med Chem 14: 1399-1407, 2007
14. Fazio S, Palmieri EA, Biondi B, Cittadini A, Sacca L: The role of the GH-IGF-I axis in the regulation of myocardial growth: From experimental models to human evidence. Eur J Endocrinol 142: 211-216, 2000
15. Smith JC, Evans LM, Wilkinson I, Goodfellow J, Cockcroft JR, Scanlon MF, Davies JS: Effects of GH replacement on endothelial function and large-artery stiffness in GH-deficient adults: A randomized, doubleblind, placebo-controlled study. Clin Endocrinol (Oxf) 56: 493-501, 2002
16. Beshyah SA, Johnston DG: Cardiovascular disease and risk factors in adults with hypopituitarism. Clin Endocrinol (Oxf) 50: 1-15, 1999
17. Climent VE, Pico A, Sogorb F, Aznar S, Lip GY, Marin F: Growth hormone therapy and the heart. Am J Cardiol 97: 1097-1102, 2006
18. Maison P, Chanson P: Cardiac effects of growth hormone in adults with growth hormone deficiency: A meta-analysis. Circulation 108: 2648-2652, 2003
19. Colao A, Di Somma C, Savanelli MC, De Leo M, Lombardi G: Beginning to end: Cardiovascular implications of growth hormone (GH) deficiency and GH therapy. Growth Horm IGF Res 16[Suppl A]: S41-S48, 2006
20. Le Corvoisier P, Hittinger L, Chanson P, Montagne O, Macquin-Mavier I, Maison P: Cardiac effects of growth hormone treatment in chronic heart failure: A meta-analysis. J Clin Endocrinol Metab 92: 180-185, 2007
21. Cittadini A, Isgaard J, Monti MG, Casaburi C, Di Gianni A, Serpico R, Iaccarino G, Sacca L: Growth hormone prolongs survival in experimental postinfarction heart failure. J Am Coll Cardiol 41: 2154-2163, 2003
22. Kaskel F: Chronic renal disease: A growing problem. Kidney Int 64: 1141-1151, 2003
23. Rabkin R, Sun DF, Chen Y, Tan J, and Schaefer F: Growth hormone resistance in uremia, a role for impaired JAK/STAT signaling. Pediatr Nephrol 20: 313-318, 2005
24. Rabkin R: Therapeutic use of growth factors in renal disease. In: Kopple and Massry's Nutrional Management of Renal Disease, edited by Massry SG, Kopple JD, Philadelphia, Lippincott Williams & Wilkins, 2003, pp 581-592
25. Schaefer F, Chen Y, Tsao T, Nouri P, Rabkin R: Impaired JAK-STAT signal transduction contributes to growth hormone resistance in chronic uremia. J Clin Invest 108: 467-475, 2001
26. Zheng Z, Sun DF, Tummala P, Rabkin R: Cardiac resistance to growth hormone in uremia. Kidney Int 67: 858-866, 2005
27. Woelfle J, Rotwein P: In vivo regulation of growth hormone-stimulated gene transcription by STAT5b. Am J Physiol Endocrinol Metab 286: E393-E401, 2004
28. Woelfle J, Billiard J, Rotwein P: Acute control of insulin-like growth factor-I gene transcription by growth hormone through Stat5b. J Biol Chem 278: 22696-22702, 2003
29. Kinugawa S, Tsutsui H, Ide T, Nakamura R, Arimura K, Egashira K, Takeshita A: Positive inotropic effect of insulin-like growth factor-1 on normal and failing cardiac myocytes. Cardiovasc Res 43: 157-164, 1999
30. Tajima M, Weinberg EO, Bartunek J, Jin H, Yang R, Paoni NF, Lorell BH: Treatment with growth hormone enhances contractile reserve and intracellular calcium transients in myocytes from rats with postinfarction heart failure. Circulation 99: 127-134, 1999
31. Kelley KW, Weigent DA, Kooijman R: Protein hormones and immunity. Brain Behav Immun 21: 384-392, 2007
32. Kennedy DJ, Vetteth S, Periyasamy SM, Kanj M, Fedorova L, Khouri S, Kahaleh MB, Xie Z, Malhotra D, Kolodkin NI, Lakatta EG, Fedorova OV, Bagrov AY, Shapiro JI: Central role for the cardiotonic steroid marinobufagenin in the pathogenesis of experimental uremic cardiomyopathy. Hypertension 47: 488-495, 2006
33. Qing DP, Ding H, Vadgama J, Wu YY, Kopple JD: Elevated myocardial cytosolic calcium impairs insulin-like growth factor-1-stimulated protein synthesis in chronic renal failure. J Am Soc Nephrol 10: 84-92, 1999
34. Groesbeck MD, Parlow AF: Highly improved precision of the hypophysectomized female rat body weight gain bioassay for growth hormone by increased frequency of injections, avoidance of antibody formation, and other simple modifications. Endocrinology 120: 2582-2590, 1987
35. Ericsson F, Filho JC, Lindgren BF: Growth hormone treatment in hemodialysis patients: A randomized, double-blind, placebo-controlled study. Scand J Urol Nephrol 38: 340-347, 2004
36. Sesmilo G, Biller BM, Llevadot J, Hayden D, Hanson G, Rifai N, Klibanski A: Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency: A randomized, controlled clinical trial. Ann Intern Med 133: 111-122, 2000
37. Uronen-Hansson H, Allen ML, Lichtarowicz-Krynska E, Aynsley-Green A, Cole TJ, Höidén-Guthenberg I, Fryklund L, Klein N: Growth hormone enhances proinflammatory cytokine production by monocytes in whole blood. Growth Horm IGF Res 13: 282-286, 2003
38. Chen Y, Sun D, Krishnamurthy VM, Rabkin R: Endotoxin attenuates growth hormone-induced hepatic insulin-like growth factor I expression by inhibiting JAK2/STAT5 signal transduction and STAT5b DNA binding. American J Physiol Endocrinol Metab 292: E1856-E1862, 2007
39. Bruel A, Oxlund H, Nyengaard JR: The total length of myocytes and capillaries, and total number of myocyte nuclei in the rat heart are time-dependently increased by growth hormone. Growth Horm IGF Res 15: 256-264, 2005
40. Grimm D, Cameron D, Griese DP, Riegger GA, Kromer EP: Differential effects of growth hormone on cardiomyocyte and extracellular matrix protein remodeling following experimental myocardial infarction. Cardiovasc Res 40: 297-306, 1998
41. Imanishi R, Ashizawa N, Ohtsuru A, Seto S, Akiyama-Uchida Y, Kawano H, Kuroda H, Nakashima M, Saenko VA, Yamashita S, Yano K: GH suppresses TGF-beta-mediated fibrosis and retains cardiac diastolic function. Mol Cell Endocrinol 218: 137-146, 2004
42. Kasinath BS, Mariappan MM, Sataranatarajan K, Lee MJ, Feliers D: mRNA translation: Unexplored territory in renal science. J Am Soc Nephrol 17: 3281-3292, 2006
43. Berger I, Piecha G, Rabkin R, Kaya N, Geldyyev A, Sun D, Chen Y, Koleganova N, Gross ML: Growth hormone treatment prevents osteoporosis in uremic rats. Histol Histopathol 22: 1231-1239, 2007
44. Landau D, Israel E, Rivkis I, Kachko L, Schrijvers BF, Flyvbjerg A, Phillip M, Segev Y: The effect of growth hormone on the development of diabetic kidney disease in rats. Nephrol Dial Transplant 18: 694-702, 2003
45. Trachtman H, Futterweit S, Schwob N, Maesaka J, Valderrama E: Recombinant human growth hormone exacerbates chronic puromycin aminonucleoside nephropathy in rats. Kidney Int 44: 1281-1288, 1993
46. Mahan JD: Applying the Growth Failure in CKD Consensus Conference: Evaluation and treatment algorithm in children with chronic kidney disease. Growth Horm IGF Res 16[Suppl A]: S68-S78, 2006
47. Yang R, Bunting S, Gillett N, Clark R, Jin H: Growth hormone improves cardiac performance in experimental heart failure. Circulation 92: 262-267, 1995
48. Hongo M, Hironaka E, Yokoseki O, Watanabe N, Shibamoto T, Owa M, Ryoke T: Effects of growth hormone following chronic angiotensin-converting enzyme inhibition in chronic heart failure: Their relation to infarct size. Cardiovasc Drugs Ther 15: 241-249, 2001
49. Jin H, Yang R, Gillett N, Clark RG, Ko A, Paoni NF: Beneficial effects of growth hormone and insulin-like growth factor-1 in experimental heart failure in rats treated with chronic ACE inhibition. J Cardiovasc Pharmacol 26: 420-425, 1995
50. Wannenburg T, Khan AS, Sane DC, Willingham MC, Faucette T, Sonntag WE: Growth hormone reverses age-related cardiac myofilament dysfunction in rats. Am J Physiol Heart Circ Physiol 281: H915-H922, 2001
51. Khan AS, Lynch CD, Sane DC, Willingham MC, Sonntag WE: Growth hormone increases regional coronary blood flow and capillary density in aged rats. J Gerontol A Biol Sci Med Sci 56: B364-371, 2001
52. Meyers DE, Cuneo RC: Controversies regarding the effects of growth hormone on the heart. Mayo Clin Proc 78: 1521-1526, 2003
53. Demers C, McKelvie RS: Growth hormone therapy in heart failure: Where are we now? Congest Heart Fail 9: 84-90, 2003
54. Feldt-Rasmussen B, Lange M, Sulowicz W, Gafter U, Lai KN, Wiedemann J, Christiansen JS, El Nahas M: Growth hormone treatment during hemodialysis in a randomized trial improves nutrition, quality of life, and cardiovascular risk. J Am Soc Nephrol 18: 2161-2171, 2007
55. Jensen PB, Ekelund B, Nielsen FT, Baumbach L, Pedersen FB, Oxhoj H: Changes in cardiac muscle mass and function in hemodialysis patients during growth hormone treatment. Clin Nephrol 53: 25-32, 2000
56. Mattfeldt T, Mall G, Gharehbaghi H, Moller P: Estimation of surface area and length with the orientator. J Microsc 159: 301-317, 1990
57. Henquell L, Honig CR: Intercapillary distances and capillary reserve in right and left ventricles: Significance for control of tissue po2. Microvasc Res 12: 35-41, 1976
58. Gross M-L, Ritz E, Korsch M, Adamczak M, Weckbach M, Mall G, Berger I, Hansen A, Amann K: Effects of estrogens on cardiovascular structure in uninephrectomized SHRsp rats. Kidney Int 67: 849-857, 2005
59. Sun DF, Chen Y, Rabkin R: Work-induced changes in skeletal muscle IGF-1 and myostatin gene expression in uremia. Kidney Int 70: 453-459, 2006
60. Glantz S: Primer of Biostatistics, 5th Ed., New York, McGraw-Hill, 2002, pp 92-103